vTv Therapeutics Inc.
4170 Mendenhall Oaks Parkway
Tel: 336-841-0300 ext 100
74 articles with vTv Therapeutics Inc.
vTv Therapeutics Announces Licensing Agreement with Newsoara Biopharma Co. Ltd. to Rights for vTv’s PDE4 Inhibitor in China and Other Pacific Rim Territories
vTv Therapeutics will receive an upfront payment and will be eligible to receive future development and commercialization milestones as well as royalties on sales of approved products.
North Carolina-based vTv Therapeutics revealed some potential hope for Alzheimer’s patients from its Phase III azeliragon study despite the drug failing to meet primary endpoints in April.
Only days after UK-based Mereo BioPharma canceled its plans for an initial public offering (IPO) on the Nasdaq Global Market, Framingham, Massachusetts-based Alzheon dropped its IPO plans.
Switzerland-based Novartis is buying Bannockburn, Illinois-based AveXis for $8.7 billion. This could spell big trouble for Cambridge, Massachusetts-based Biogen.
Yet another Alzheimer’s drug has failed in late-stage clinical trials. vTv Therapeutics’ azeliragon failed to meet either co-primary efficacy endpoint in its Phase III STEADFAST clinical trial. It was being evaluated in patients with mild Alzheimer’s disease.
vTv Therapeutics Announces Completion of Phase 1b Study Evaluating TTP399 for the Treatment of Type 1 Diabetes
Simplici-T1 is an adaptive Phase 1b/2 study being conducted with support from JDRF.
vTv Therapeutics Reports 2017 Fourth Quarter and Full Year Financial and Operational Results and Recent Highlights
“We made tremendous progress across the spectrum of our Alzheimer’s and diabetes programs this past year, and look forward to continuing this momentum in 2018 as we anticipate reporting topline results in April from Part A of our Phase 3 STEADFAST study of azeliragon in patients with mild Alzheimer’s disease,” said Steve Holcombe, president and CEO of vTv Therapeutics.
It seems that the primary news surrounding Alzheimer's disease research has been nothing but negative for years.
Under the terms of the agreement, vTv Therapeutics will receive an upfront payment and will be eligible to receive future development and commercialization milestones as well as royalties on sales of approved products. vTv Therapeutics will also receive shares of Reneo Pharmaceuticals' common stock.
vTv Therapeutics Announces Licensing Agreement With Hangzhou Zhongmei Huadong Pharmaceutical Co. to Rights for vTv’s GLP-1r Agonist Diabetes Program in China and Other Pacific Rim Territories
Under the terms of the agreement, vTv Therapeutics will run a Phase 2 Multi-Regional Clinical Trial (MRCT) including sites in the US and other regions in the Pacific Rim.
vTv to Host Key Opinion Leader Event to Discuss the Current State of Clinical Development in Alzheimer’s Disease
vTv announced that the Company will host a key opinion leader (KOL) presentation and webcast focused on the current state of clinical development in Alzheimer’s disease in New York City on Thursday, November 16, 2017 from 8:00 am to 10:00 am ET.
Results from the Phase1b part of the study are expected in early 2018.
vTv Therapeutics provided a corporate update and reported financial and operational results for the third quarter ended September 30, 2017.
vTv is currently studying azeliragon in two identical, randomized, double-blind, placebo-controlled Phase 3 trials investigating its efficacy as a potential treatment of mild Alzheimer’s disease.
vTv Therapeutics Presents Further Dose Response Analysis From Phase II Study Of Its GLP-1 Receptor Agonist At 53rd Annual Meeting Of The European Association For The Study Of Diabetes
JDRF And vTv Therapeutics Announce Collaboration On Phase II Study Of Novel Treatment For Type 1 Diabetes
vTv Therapeutics To Present Two Posters At The 2017 Alzheimer's Association International Conference
vTv Therapeutics Presents Data Highlighting Further Potential Of TTP273 At American Diabetes Association 77th Scientific Sessions